MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Strona główna・Stock List・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Open

SectorHealthcare

14.99 -0.33

Buy Sell

Overview

Share price change

24h

Current

Min

14.11

Max

15.17

Key metrics
By Trading Economics
Income	227M
Sales	139M
P/E Sector Avg	5.396 56.063
Profit margin	163.843
Employees	1,796
EBITDA	1.3M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+32.1% upside

Market Stats
By TradingEconomics
Market Cap	2.6B
Previous open	15.32
Previous close	14.99

News Sentiment

By Acuity

50%

166 / 349 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

14.24 / 14.78 Support & Resistance

Hutchison China MediTech Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

2 kwi 2026, 17:11 UTC

Major Market Movers

Major News Events

Home Depot Shares Hit 52-Week Low as Iran War Threatens Housing Rebound

2 kwi 2026, 17:10 UTC

Major News Events

ECB's Next Move Likely a Rate Rise, But Timing Unclear Amid Iran War, Villeroy Says

3 kwi 2026, 00:00 UTC

Major News Events

How Insulated Is the U.S. Economy From the Iran War? -- WSJ

2 kwi 2026, 23:47 UTC

Market Talk

Major News Events

Nikkei Might Rise After Thursday's Selloffs -- Market Talk

2 kwi 2026, 21:05 UTC

Acquisitions, Mergers, Takeovers

Starbucks: Under the Terms of the Agreement, Funds Managed by Boyu Cap Now Hold a 60% Stake in Starbucks China Retail Ops >SBUX

2 kwi 2026, 21:05 UTC

Acquisitions, Mergers, Takeovers

Starbucks: Retains 40% Ownership Interest and Continues to Own and License the Brand and Intellectual Property to JV >SBUX

2 kwi 2026, 21:05 UTC

Acquisitions, Mergers, Takeovers

Starbucks: Joint Venture Is Designed to Enhance Starbucks Ability to Expand Footprint, Deepen Local Relevance >SBUX

2 kwi 2026, 21:05 UTC

Acquisitions, Mergers, Takeovers

Starbucks and Boyu Cap: Finalize Joint Venture to Accelerate Long-Term Growth in China

2 kwi 2026, 21:01 UTC

Major News Events

Investors Waver after Trump Speech on Iran, Ending Two-Day Surge in Stocks -- WSJ

2 kwi 2026, 20:59 UTC

Acquisitions, Mergers, Takeovers

Starbucks and Boyu Capital Finalize China JV

2 kwi 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2 kwi 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

2 kwi 2026, 20:41 UTC

Earnings

These Stocks Are Today's Movers: Tesla, Globalstar, Blue Owl, United Airlines, Carnival, Lumentum, and More -- Barrons.com

2 kwi 2026, 20:32 UTC

Market Talk

Higher Gas Prices Intensify K-Shaped Economy -- Market Talk

2 kwi 2026, 20:30 UTC

Acquisitions, Mergers, Takeovers

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2 kwi 2026, 20:09 UTC

Market Talk

Eli Lilly On More Equal Footing With Rival With Weight-Loss Pill -- Market Talk

2 kwi 2026, 20:01 UTC

Acquisitions, Mergers, Takeovers

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2 kwi 2026, 19:46 UTC

Market Talk

Is Oil the New GameStop? -- Market Talk

2 kwi 2026, 19:35 UTC

Market Talk

U.S. Natural Gas Falls As Storage Injection Season Gets Under Way -- Market Talk

2 kwi 2026, 19:29 UTC

Acquisitions, Mergers, Takeovers

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2 kwi 2026, 19:24 UTC

Market Talk

Major News Events

Oil Futures Jump Ahead of Long Weekend -- Market Talk

2 kwi 2026, 19:20 UTC

Market Talk

Nike Has Yet to Show That a Turnaround is on Horizon -- Market Talk

2 kwi 2026, 19:01 UTC

Acquisitions, Mergers, Takeovers

Union Pacific: ATDA Agreement to Guarantee Jobs for Life for Union Employees After Norfolk Southern Deal

2 kwi 2026, 19:00 UTC

Acquisitions, Mergers, Takeovers

Union Pacific: Agreement Reached With American Train Dispatchers Association

2 kwi 2026, 18:24 UTC

Acquisitions, Mergers, Takeovers

Globalstar Stock Rises on Amazon Deal Report. Why Apple Could Scuttle the Launch. -- Barrons.com

2 kwi 2026, 17:44 UTC

Market Talk

Major News Events

Oil Supply Squeeze Puts Refiners in a Quandary -- Market Talk

2 kwi 2026, 17:32 UTC

Major News Events

Amazon to Boost Fuel Surcharges on Third-Party Sellers as Costs Rise -- Barrons.com

2 kwi 2026, 17:26 UTC

Earnings

These Stocks Are Today's Movers: Tesla, Globalstar, Blue Owl, United Airlines, Carnival, Lumentum, and More -- Barrons.com

2 kwi 2026, 17:17 UTC

Market Talk

Shares of Canadian Exports Heading to U.S. Continues to Slide -- Market Talk

2 kwi 2026, 17:09 UTC

Market Talk

Major News Events

Oil Holds Gains After Trump Speech Disappointed Market -- Market Talk

Peer Comparison

Price change

Hutchison China MediTech Ltd ADR Forecast

Price Target

By TipRanks

32.1% upside

12 Months Forecast

Average 20 USD 32.1%

High 20 USD

Low 20 USD

Based on 1 Wall Street analysts offering 12 month price targets forHutchison China MediTech Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to Hutchison China MediTech Ltd ADR - Dist in the past 3 months.

Technical Score

By Trading Central

14.24 / 14.78Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

166 / 349 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.